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Abstract
Background: Human fetal midbrain-derived neural progenitor cells (NPCs) may deliver a tissue source for drug screening
and regenerative cell therapy to treat Parkinson’s disease. While glutamate and GABAA receptors play an important role in
neurogenesis, the involvement of glycine receptors during human neurogenesis and dopaminergic differentiation as well as
their molecular and functional characteristics in NPCs are largely unknown.
Methodology/Principal Findings: Here we investigated NPCs in respect to their glycine receptor function and subunit
expression using electrophysiology, calcium imaging, immunocytochemistry, and quantitative real-time PCR. Whole-cell
recordings demonstrate the ability of NPCs to express functional strychnine-sensitive glycine receptors after differentiation
for 3 weeks in vitro. Pharmacological and molecular analyses indicate a predominance of glycine receptor heteromers
containing a2b subunits. Intracellular calcium measurements of differentiated NPCs suggest that glycine evokes
depolarisations mediated by strychnine-sensitive glycine receptors and not by D-serine-sensitive excitatory glycine
receptors. Culturing NPCs with additional glycine, the glycine-receptor antagonist strychnine, or the Na
+-K
+-Cl
2 co-
transporter 1 (NKCC1)-inhibitor bumetanide did not significantly influence cell proliferation and differentiation in vitro.
Conclusions/Significance: These data indicate that NPCs derived from human fetal midbrain tissue acquire essential glycine
receptor properties during neuronal maturation. However, glycine receptors seem to have a limited functional impact on
neurogenesis and dopaminergic differentiation of NPCs in vitro.
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Introduction
Glycine is an important inhibitory neurotransmitter in the adult
central nervous system acting through ionotropic glycine receptors
that are most prominently expressed in the brainstem and spinal
cord [1–3]. These receptors belong to the superfamily of Cys-
loop receptors such as GABAA, nicotinic acetylcholine, and 5-
HT3 receptors [4]. As other members of this Cys-loop family,
glycine receptors form homomeric or heteromeric pentamers with
each of the five subunits arranged around a central ion-conducting
pore [5–7]. Similar to GABAA receptors in the adult central
nervous system, the strychnine-sensitive glycine receptors are
involved in regulating inhibitory chloride influx to stabilise the
resting membrane potential of neurons. In humans, only four
functional glycine receptor subunits have been identified, a1-3 and
b [8], which are likely to exist in heteromeric ab combinations [3].
The a4 subunit gene is a pseudo-gene in humans and there is little
evidence for its functional expression in rats [7,9]. Besides
inhibitory glycine receptors, a strychnine-insensitive excitatory
glycine receptor contains NMDA receptor subunits from the NR3
family [10].
Defects in glycinergic neurotransmission can result in the
neurological motor disorder hyperekplexia which is characterised
by a disinhibited startle response [11,12]. This primary startle
syndrome is mostly autosomal dominant and is caused by
mutations in the glycine transporter, the a1 subunit, or less
frequently by mutations in the b subunit [13–16]. However, the
genetic basis of many cases of hyperekplexia and paroxysmal
movement disorders remains unresolved [17]. Glycine receptors
containing the a3 subunit in the spinal cord have been recognised
as therapeutic target to treat inflammatory pain syndromes [18].
Glycine receptors play a major role in the excitability of spinal
cord and brain stem neurons. During development, the receptor
properties undergo molecular changes resulting in modifications of
their physiological function. In rats, a developmental switch from
a2 homomeric glycine receptors to a1b heteromeric subtypes
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out of the a2 subunit, however, has no obvious effect on the
behavioural phenotype and neuronal development although it
eliminates a tonic glycine-gated chloride current in mouse
embryonic cortical neurons [19]. The receptor subtype expression
in mouse spinal neurons during in vitro development switches
similarly from a monomeric a subunit or heteromeric a2b in
immature neurons to an a1b isoform in mature neurons.
Furthermore, the formation of postsynaptic glycine receptor
clusters as well as the receptor affinity to glycine, strychnine, and
Zn
2+ increases during development [20].
In contrast to the adult central nervous system, a high
expression of the Na
+-K
+-Cl
2 co-transporter 1 (NKCC1, a Cl
2
importer) and a low expression of the K
+-Cl
2 co-transporter 2
(KCC2, a Cl
2 exporter) in neural progenitors and immature
neurons determine a high intracellular Cl
2 concentration leading
to GABA-induced depolarisations [21–24]. Glycine-induced acti-
vation of strychnine-sensitive glycine receptors can also lead to
hyper- or depolarising responses of the target cells depending on
the intracellular Cl
2 concentration [7]. During neocortical
development a depolarising glycine-gated Cl
2 efflux stimulates
the calcium influx [25] necessary for the development of numerous
neuronal specialisations including glycinergic synapses [26].
However, the involvement of glycine receptors in human
neurogenesis and dopaminergic differentiation as well as their
molecular and functional characteristics in human neural progen-
itor cells (NPCs) are largely unknown.
The proliferation and differentiation of NPCs enables to study
human neurogenesis in vitro [24,27–32] which shall help to
translate neural stem cell therapy for neurodegenerative diseases
[33–35]. Long-term expanded human mesencephalic NPCs
maintain their proliferative capacity and continue to give rise to
neurons that express tyrosine hydroxylase (TH) and also release
dopamine [36]. The present study analyses human midbrain-
derived NPCs in respect to their glycine receptor expression and
function. We also investigated whether glycine, the glycine-
receptor antagonist strychnine, or the NKCC1-inhibitor bumet-
anide are able to influence neurogenesis and dopaminergic
differentiation in vitro.
Materials and Methods
Cell Culture
Human neural progenitor cells were derived from CNS tissue of
aborted human fetuses (gestational week 10–16) with the informed
written consent of all mothers involved in this study. All
experiments were approved by the Ethics Committees of the
University of Leipzig and the Hannover Medical School,
Germany and are in accordance with all state and federal
guidelines. The human fetal tissue was washed with sterile Hank’s
buffered salt solution and dissected into mesencephalic and non-
mesencephalic primary tissue samples. The tissue samples were
mechanically separated into small pieces, incubated in 0.1 mg/ml
papain solution (Roche, Mannheim, Germany), supplemented
with 10 mg/ml DNase (Roche) for 30 min at 37uC, then washed
three times with Hank’s buffered salt solution followed by an
incubation with 50 mg/ml antipain solution (Roche) for 30 min at
37uC. After three further washing steps the samples were
homogenised by gentle trituration using fire-polished pasteur
pipettes. The quality of the tissue was assessed as described
previously [27,28].
Propagation of human mesencephalic neural progenitor cells
(NPCs) was performed in a monolayer by plating onto poly-L-
ornithine (Sigma, Taufkirchen, Germany) and fibronectin (Milli-
pore, Billerica, MA, USA) coated culture dishes at a density of
30000 cells/cm
2. For expansion of NPCs, we used a xeno-free
medium (Dulbecco’s modified Eagle’s medium/F12) supplement-
ed with epidermal growth factor and basic fibroblast growth factor
(20 ng/ml each; both from PromoCell, Heidelberg, Germany),
2% B27 (Invitrogen, Karlsruhe, Germany), and 1% penicillin/
streptomycin (PAA, Pasching, Austria). Cells could be expanded
for prolonged periods (.10 passages) in reduced atmospheric
oxygen (3%) as described previously [36–38]. For differentiation
NPCs were plated on poly-L-lysine coated 35 mm dishes (Sigma)
at a density of 1610
5/cm
2. Neuronal differentiation was induced
by replacement of the expansion medium by a mitogen-free
standard medium consisting of Neurobasal (Invitrogen) supple-
mented with 2% B27 (Invitrogen), 1% Glutamax, interleukin-1b
(100 pg/ml; Sigma), 5 mM forskolin (Sigma), and 0.1% gentamy-
cin (Invitrogen). The differentiation medium was replaced twice a
week during the whole incubation protocol. Note that the
expansion medium contained 250 mM glycine (Sigma) and the
standard differentiation medium 400 mM glycine.
Electrophysiology
Whole-cell patch-clamp recordings of ligand- and voltage-gated
ion channels were performed on human midbrain-derived NPCs
that had been differentiated for 3 weeks in vitro. Experiments were
carried out in the voltage- or current-clamp mode (holding
potential 270 mV) at room temperature using an EPC-9 amplifier
and PulseFit software (HEKA, Lambrecht, Germany). The
external bath solution contained (in mM): 142 NaCl, 1 CaCl2,
8 KCl, 6 MgCl2, 10 glucose, and 10 HEPES (pH 7.4;
320 mOsm). Micropipettes were formed from thin-walled boro-
silicate glass (BioMedical Instruments, Zo ¨llnitz, Germany) with a
Flaming Brown electrode puller P-97 (Sutter Instrument Co.,
Novato, CA, USA) and a Micro Forge (Narishige, Tokio, Japan).
Electrodes had resistances of 3–5 MV when filled with the internal
solution containing (in mM): 153 KCl, 1 MgCl2, 10 HEPES,
5 EGTA, and 2 MgATP (pH 7.3; 305 mOsm). The combination
of internal and external solutions produced a chloride equilibrium
potential near 0 mV for glycine receptor recordings.
All solvents and chemicals for pharmacological experiments
were purchased from Sigma or Tocris (Germany). The stock
solutions were prepared in DMSO or external recording solution
as appropriate (1–300 mM). A fresh stock solution of tropisetron
(1 mM) was prepared at the day of experiments. The drugs were
dissolved in external solution containing DMSO at a maximal
final concentration of 0.1%. All drugs were applied rapidly via
gravity using a modified SF-77B perfusion fast-step system
(Warner Instruments Inc., Hamden, CT, USA) as described
previously [39]. For the glycine dose-response curve seven
increasing concentrations (10 mM–10 mM) were applied for
2 sec on NPCs. For pharmacological characterisation of glycine
receptors, positive and negative modulators were co-applied for
2 sec with an EC70 of glycine (300 mM). The intervals between
applications were 30 sec, after co-applying strychnine 1 min
intervals were allowed for wash out.
Whole-cell currents were low-pass filtered at 1–5 kHz, digitized
at 10 kHz, and analysed with PulseFit (HEKA) and GraphPad
Prism (GraphPad Software, San Diego, CA, USA). Peak currents
of each investigated cell were normalised to the maximal glycine-
evoked peak current (for glycine dose-response curves) or to the
glycine EC70 control that was applied prior to the co-application of
each tested modulator. To obtain nonlinear regression concen-
tration-response plots mean peak currents 6 SEM were fitted to a
sigmoidal function using a four parameter logistic equation
(sigmoidal concentration-response) with a variable slope. The
Glycine Receptors in Human NPCs
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was I=Imax/1+10
(LogEC502Logdrug)xHill slope where I was the peak
current at a given concentration. Numerical data of all experi-
ments were expressed as means 6 SEM. Statistical differences
were calculated by using Student’s t test (two tailed, unpaired) and
considered significant at p,0.05 (Table 1).
Quantitative Real-time PCR
After 1 and 3 weeks of differentiation in vitro, human
mesencephalic NPCs from 3 cell lines were harvested and total
RNA isolated using the Trizol reagent (Invitrogen). Reverse
transcription of 800 ng total RNA per reaction was carried out
using oligo-dT primer and Superscript II reverse transcriptase
(Invitrogen).
Quantitative real-time PCR was done using cDNA from 30 ng
total RNA, 0.6 mM forward and reverse primers, Platinum-SYBR
GreenH qPCR Supermix (Invitrogen), and 100 nM 6-carboxy-X-
rhodamine (ROX) using the following protocol in an MX 3000P
instrument (Stratagene, La Jolla, CA, USA): 2 min 50uC, 2 min
95uC and 50 cycles of 15 sec 95uC, 30 sec 60uC. To confirm a
single amplicon a product melting curve was recorded. The
correct amplicon size was asserted by agarose gel electrophoresis
using low molecular weight DNA ladder (New England Biolabs,
Ipswich, MA, USA). Oligonucleotide primers for human glycine
receptor subunits a1–4 and b (Table 1) were designed to flank
intron sequences, if feasible, using Primer 3 software.
Cycle threshold (Ct) values were placed within the exponential
phase of the PCR as described previously [40]. Ct values of 3
independent experiments, each performed in duplicate, were
normalised to b2-microglobulin (Ct – Ct b2-microglobulin=DCt).
DCt values were used to calculate the relative subunit expression
levels and are given as means 6 SEM (Table 2). Note, a low DCt
value represents a high expression level. The expression of glycine
receptor subunits was statistically evaluated by subjecting DCt
values to a one-way ANOVA and Newman-Keuls post test for
multiple comparisons taking statistical significance as p,0.05.
Calcium Imaging
Measurements of the intracellular Ca
2+ concentration [Ca
2+]i in
human mesencephalic NPCs were performed as described
previously [24] using a monochromator-based imaging system
(TILL Photonics, Gra ¨felfing, Germany). Cells were loaded with
5 mM fura-2-AM (Invitrogen) supplemented with 0.01% Pluronic
F127 for 30 min at 20–22uC in a standard bath solution
containing (mM): 140 NaCl, 5 KCl, 2 CaCl2, 10 glucose and 10
HEPES, adjusted to pH 7.4 with NaOH. For measurements of
[Ca
2+]i, cells were placed in a recording chamber and continu-
ously perfused with standard bath solution at a rate of 5 ml/min.
Fluorescence was excited at 340 and 380 nm and emitted
fluorescence intensities from single cells were acquired at intervals
of 2 s.
Table 1. Functional properties of human mesencephalic NPCs after differentiation for 3 weeks in vitro.
Functional properties of differentiated NPCs Glycine-responsive NPCs (n=53) Glycine-nonresponsive NPCs (n=26)
Peak Na
+-current 273612 pA 2120623 pA *
Peak Na
+-current/pF 8.461.7 pA/pF 10.662.2 pA/pF
Peak K
+-current 9486107 pA 12466131 pA
Peak K
+-current/pF 106611 pA/pF 108611 pA/pF
Membrane capacitance 9.160.6 pF 12.060.9 pF **
Membrane potential 230.262.5 mV 233.963.0 mV
Input resistance 470653 MV 6486119 MV
Voltage-gated currents and passive membrane properties of NPCs displaying currents during application of glycine (glycine-responsive) are shown in comparison to
cells without detectable glycine-induced current (,5 pA, nonresponsive). All data are given as means 6 SEM (*p,0.05, **p,0.01, t-test).
doi:10.1371/journal.pone.0036946.t001
Table 2. Quantitative real-time PCR analysis of glycine receptor subunit expression in human mesencephalic NPCs after 1 and 3
weeks of differentiation.
Glycine receptor subunit Sequence (forward; reverse) Product (bp)
DCt values (3 weeks
differentiation)
DCt values (1 week
differentiation)
a1 TAAGGAGGCTGAAGCTGCTC;
ATGTTGCAGCTCACGTTCAC
144 16.061.2 13.160.8
a2 ACGATGACCACCCAGAGTTC;
CCAGTAAGGCAGCAAACACA
115 6.360.2 * 10.461.2
a3 TAAGCCATTCGCAAGATGTG;
TTTGCACCCAATTACACTGC
130 10.061.3 10.160.5
a4 CTCACCATGACCACCCAGA;
GCGAACACAAAGAGCAGACA
107 12.560.5 * 17.761.2
b CACATGCGTGGAAGTCATCT;
GGAAAGCCAGGAGAGAACAA
93 5.460.03 * 7.860.6
Primer sequences, amplification product in base pairs, and mean DCt values 6 SEM (n=3) are given for each investigated receptor subunit (*p,0.05, t-test). Note, a low
DCt value represents a high expression level.
doi:10.1371/journal.pone.0036946.t002
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To investigate the influence of additional glycine, the glycine-
receptor antagonist strychnine, and the NKCC1-inhibitor bumet-
anide on NPCs in vitro, separate experiments were performed in
which some cells were treated with two distinct concentrations of
glycine (1 and 10 mM), strychnine, or bumetanide (1 and 10 mM)
during proliferation (2 weeks) and differentiation (1 and 3 weeks).
The stock solution was prepared by dissolving glycine in distilled
water at a concentration of 100 mM, strychnine in ethanol and
bumetanide in DMSO at a concentration of 10 mM. The drugs
were renewed with every media change. Besides using the
standard differentiation medium, NPCs were also differentiated
for 1 week by a novel mitogen-free medium to promote
dopaminergic neurogenesis consisting of Neurobasal (Invitrogen)
supplemented with 2% B27 (Invitrogen), 1% Glutamax, 100 mM
dbcAMP (Sigma), 10 mM forskolin (Sigma), 100 mM fusaric acid
(Sigma), and 0.1% gentamycin (Invitrogen).
The determination of cell number and protein content as well as
the Western blotting of treated and untreated NPCs were
performed as described previously [27,28]. Primary antibodies
used for Western blotting were as follows: mouse monoclonal anti-
PCNA (proliferating cell nuclear antigen; Santa Cruz, Heidelberg,
Germany), mouse monoclonal anti-Bcl-2 (B cell lymphoma 2;
Santa Cruz), mouse monoclonal anti-actin (MP Biomedicals,
Eschwege, Germany), rabbit polyclonal anti-ß-tubulin III (Cov-
ance, Freiburg, Germany), rabbit polyclonal anti-TH (Santa Cruz,
Heidelberg, Germany), and rat anti-GFAP (glial fibrillary acidic
protein; Zymed, San Francisco, CA, USA).
Immunocytochemistry
For immunolabelling, differentiated cells were fixed with 4%
paraformaldehyde for 10 min. The unspecific binding was blocked
in PBS supplemented with 10% fetal calf serum and membranes
were permeabilized with 0.3% Triton X-100 for 1 h. Cultures
were incubated with primary antibodies for 2 h at room
temperature. The following primary antibodies were used for
immunofluorescence analysis: rabbit polyclonal anti-TH (Santa
Cruz) diluted 1:500, mouse monoclonal anti-b-tubulin III (1:500,
Sigma), mouse monoclonal anti-MAP2 (1:300, Pharmingen,
Heidelberg, Germany), rat monoclonal anti-GFAP (1:500,
Zymed). The cells were incubated for 1 h at room temperature
with fluorescent secondary antibodies conjugated either to Alexa
Fluor 488 or Alexa Fluor 594 (1:500, Invitrogen). Nuclei were
stained with 49,6-diamidino-2-phenylindole (DAPI, 0.5 mg/ml,
Calbiochem, San Diego, CA, USA) for 30 min at room
temperature.
For immunocytochemical staining of glycine receptor subunits
in NPCs after 3 weeks of standard differentiation, we used a
modified protocol. Unspecific binding was blocked with 5%
donkey serum (Dianova, Hamburg, Germany) and membranes
Figure 1. Glycine-induced Ca
2+ signalling in fura-2 loaded NPCs differentiated for 1 or 3 weeks. A, Changes in [Ca
2+]i were evoked by
application of 100 mM glycine (Gly), 100 mM D-serine (D-Ser), 20 mM strychnine (Stry), and 50 mM KCl in cells differentiated for 3 weeks. The trace is
the mean response of eight cells from a representative experiment. B, Summary of the [Ca
2+]i response amplitudes (n=22–27 cells; means 6 SEM)
and fractions of cells (n=60–75 from 86 cells) responding to different stimuli was obtained from 4 experiments as shown in A. C, NPCs differentiated
for 1 week showed smaller increases in [Ca
2+]i upon application of 100 mM glycine and 50 mM KCl. The trace is the mean response of 8 cells from a
representative experiment. D, Fractions of cells differentiated for 1 week (n=7–29 of 139 cells) or 3 weeks (n=60–75 from 86 cells) responding to
different stimuli were obtained from 5 and 4 experiments as shown in A and C, respectively.
doi:10.1371/journal.pone.0036946.g001
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antibodies (mouse monoclonal anti-glycine receptor, mAb4a,
1:250, Synaptic Systems, Goettingen, Germany; rabbit polyclonal
anti-MAP2, AB5622, 1:500, Chemicon, Nuernberg, Germany)
were incubated in PBS/5% donkey serum/0.3% Triton X-100 for
20 h at 4uC. Note, this glycine receptor antibody is specific for all
subunits. Cultures were incubated in 2% bovine serum albumin
with secondary antibodies (Alexa Fluor 488, 1:500, Invitrogen; red
fluorescent indocarbocyanine Cy3, 1: 200, Dianova) for 2 h at
room temperature. Nuclei were counter-stained as described
above.
Staining patterns were visualised by fluorescence microscopy
(Axiovert 200, Zeiss, Jena, Germany). Digital images were
acquired with an AxioCam MRc camera using the image-analysis
software AxioVision 4 (Zeiss). The portion of cells immunoreactive
for GFAP, b-tubulin III, MAP2, and TH was determined by
counting the number of immunopositive cells in relation to the
number of DAPI stained nuclei. Approximately 1000 cells were
counted within four randomly selected fields per well.
Results
We studied the functional and molecular glycine receptor
properties of human midbrain-derived NPCs following differen-
tiation using standard conditions for 1 or 3 weeks in vitro. The
effect of glycine on Ca
2+ signalling in differentiated mesencephalic
NPCs was determined using fura-2-based Ca
2+ imaging. Besides
its agonistic action on glycine receptors, glycine is also a co-agonist
along with glutamate for most NMDA receptors and can activate
NR3 subunit containing NMDA receptors in the absence of
glutamate [10]. To test for a depolarisiation-induced entry of Ca
2+
due to activation of glycine receptors as well as for a possible
involvement of glycine-activated NMDA receptors, we subse-
quently applied glycine alone or in combination with the
antagonists strychnine or D-serine. The latter, a co-agonist of
conventional NMDA receptors, was shown to inhibit currents of
NMDA receptors containing NR3 [10].
NPCs differentiated for 3 weeks showed glycine-induced Ca
2+
transients that were completely suppressed by the glycine receptor
antagonist strychnine but were only slightly affected by D-serine
(Fig. 1A). Increases in [Ca
2+]i were also evoked by application of
50 mM KCl, indicating depolarisation-dependent Ca
2+ entry. The
percentage of cells responding to glycine and KCl determined
Figure 2. Functional analysis of glycine receptors in human midbrain-derived NPCs differentiated for 3 weeks in vitro. A, Whole-cell
recordings of currents elicited by applications of increasing glycine concentrations (10 mM – 10 mM). B, Glycine dose-response curve (EC50=99.2 mM,
hillslope=0.95, n=10) indicates a glycine EC70 of 300 mM that was used in further electrophysiological experiments.
doi:10.1371/journal.pone.0036946.g002
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from 85), respectively (Fig. 1B). The increases in [Ca
2+]i elicited by
subsequent application of 100 mM glycine, of 100 mM glycine in
the presence of either D-serine or strychnine, and of 50 mM KCl
were 108621 nM (n=22), 74617 nM (n=22), 862 nM (n=22),
and 157627 nM (n=29), respectively (Fig. 1B). These data
suggest that glycine evokes Ca
2+ signals by activation of glycine
receptors and receptor-dependent membrane depolarisation.
Human midbrain-derived NPCs differentiated for 1 week were
less responsive to application of glycin and KCl (Fig. 1C). The
percentages of cells responding to glycine determined from these
experiments were 5% (n=7 of 139) and 70% (n=60 of 85) for
shorter (1 week) and longer (3 weeks) differentiation, respectively
(Fig. 1D). The corresponding amounts of cells showing KCl-
induced Ca
2+ signals were 21% (n=29 of 139) and 87% (n=75 of
85) for shorter and longer differentiation, respectively (Fig. 1D).
We also tested the ability of glycine to induce [Ca
2+]i changes in
undifferentiated NPCs. However, all tested cells displayed no
measurable responses to application of 100 mM glycine (n=60
from 4 experiments, data not shown).
Patch-clamp electrophysiology was performed to measure
glycine-evoked currents as well as voltage-gated sodium and
potassium currents. Whole-cell recordings revealed a current
response during rapid applications of glycine in 67% of
differentiated NPCs (n=53 from 79), which is similar to the
percentage of glycine-responsive cells in calcium imaging exper-
iments. The average peak sodium currents of glycine-responsive
NPCs (–73 pA) were significantly smaller in comparison to cells
without detectable glycine-induced current (–119 pA; Table 1).
However, NPCs expressing functional glycine receptors showed a
smaller cell membrane capacitance than cells without current
evoked by glycine (9.1 pF and 12.0 pF, respectively; Table 1).
Therefore, the relative sodium and potassium peak current
densities in pA/pF were not significantly different between these
groups of NPCs. Furthermore, there were no significant differ-
ences for peak potassium currents, resting membrane potentials,
and input resistances between both cell types (Table 1).
Rapid applications of increasing glycine concentrations
(10 mM–10 mM) on differentiated NPCs elicited desensitising
currents in a dose-dependent manner (Fig. 2A). The glycine
concentration-response plot (Fig. 2B) indicated an EC50 of
99.2 mM (95% confidence interval of Log EC50 value –4.181 to
–3.826, hillslope 0.95, n=10). Mean peak currents evoked by
glycine were 241 pA641 pA (n=53). For further pharmacological
characterisation of glycine receptors, we used co-applications of
Figure 3. Pharmacological characterisation of glycine receptors in NPCs differentiated for 3 weeks. A, Whole-cell currents evoked by a
glycine EC70 were all markedly blocked by strychnine and partly inhibited by picrotoxin, pregnenolone sulphate and a high bicuculline concentration.
In contrast to the positive modulation by 10 mM ZnCl2, a reduction of glycine currents was induced by 100 mM ZnCl2. Also, co-application of a glycine
EC70 and tropisetron showed a positive modulatory effect. This pharmacological profile suggests receptor isoforms containing a2b subunits (B, n=9–
10; all data are given as means 6 S.E.M.).
doi:10.1371/journal.pone.0036946.g003
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concentration-response plot.
All glycine-induced currents of NPCs were markedly blocked by
strychnine and partly inhibited by atropine, the neurosteroid
pregnenolone sulphate as well as by the GABAA receptor
antagonists picrotoxin and bicuculline (Fig. 3A). In contrast to
the slight inhibition of glycine currents by 100 mMZ n
2+, a small
positive modulatory effect was induced by a lower Zn
2+2concen-
tration (10 mM; Fig. 3B). Furthermore, a current potentiation of
the glycine EC70 was induced by co-application of the 5-HT3-
receptor antagonist tropisetron. The pharmacological profile of
glycine receptors in NPCs with moderate picrotoxin-sensitivity, a
differential sensitivity to Zn
2+, and a positive modulation by
tropisetron, suggests the expression of heteromeric isoforms, most
likely containing a2b subunits [41,42].
For quantitative expression analysis of glycine receptor subunits,
human midbrain-derived NPC lines (n=3) were investigated by
real-time PCR after differentiation for 1 and 3 weeks in vitro.
Statistical comparisons of DCt values (n=3 independent experi-
ments, each performed in duplicate) are summarised in Fig. 4.
While the expression of various glycine receptor subunits was not
yet markedly different after 1 week of cell maturation (Fig. 4B), we
found a predominant expression of a2 and b subunits with
significant difference to the other glycine receptor isoforms after
differentiation for 3 weeks (Fig. 4A; p,0.001, ANOVA and
Newman-Keuls post test). The expression of a2, a4 and b subunits
was significantly higher in NPCs differentiated for 3 weeks than for
1 week (Table 2; p,0.05, t-test). Interestingly, b subunit
expression was most pronounced and significantly different from
all a subunits after 3 weeks of maturation (Fig. 4A). The expression
of a1, which is the most abundant glycine receptor a subunit in the
adult nervous system, was barely detectable, whereas the a4
subunit sparsely occurred and a3 was expressed to a moderate
extent. In line with the pharmacological results, the quantitative
PCR data indicate a predominant expression of glycine receptors
containing a2 and b subunits.
Drug treatment of human mesencephalic NPCs with additional
glycine (1 and 10 mM), the glycine-receptor antagonist strychnine,
or the NKCC1-inhibitor bumetanide (1 and 10 mM) during
expansion (2 weeks) did not induce significant differences
compared to untreated controls (n=3–6) in the number of living
cells, protein content, or the cell proliferation as determined by
Western blot analysis of the proliferation marker PCNA and the
survival marker Bcl2 as well as by immunocytochemistry of the
proliferation marker Ki67 and the neural stem cell marker nestin
(data not shown). After differentiation with the standard protocol
(1 and 3 weeks) or with a novel medium to promote the
dopaminergic neurogenesis (1 week), Western blot and immuno-
cytochemical results of drug treated NPCs (n=3–6 cell lines) using
the markers GFAP, b-tubulin III, MAP2, and TH were not
significantly different from controls (data not shown).
The amount of untreated NPCs (n=3 cell lines) immunoposi-
tive for TH (0.9%), b-tubulin III (34.4%), and GFAP (31.3%) after
1 week increased moderately during a total differentiation of 3
weeks with the standard protocol to 1.6%, 39.6%, and 32.6%,
respectively. The number of MAP2-immunoreactive NPCs was
significantly higher after 3 weeks (30.5%) than 1 week (13.7%) of
maturation (n=3, p,0.05, t-test). Using a novel medium to
enhance dopaminergic neurogenesis of NPCs (n=6 cell lines)
resulted in a marked increase of TH-immunoreactive cells to 2.7%
after differentiation for 1 week. Immunocytochemical stainings
after 3 weeks of standard NPC-differentiation show that neuronal
MAP2-expressing cells are immunopositive for glycine receptor
subunits (Fig. 5).
Discussion
In this study, calcium imaging and electrophysiological record-
ings demonstrated the expression of excitatory strychnine-sensitive
glycine receptors in differentiated human midbrain-derived NPCs.
The similar voltage-gated peak currents/pF in cells with functional
glycine receptors (67%) compared to glycine-nonresponsive NPCs
(33%, Table 1) suggest that the maturation of functional glycine
Figure 4. Real time PCR analysis of glycine receptor subunits
expressed by NPCs after 1 and 3 weeks of differentiation.
Quantitative real-time PCR (SYBR green assay) was performed for each
transcript and control (b2-microglobulin). Cycle threshold (Ct) values
were normalized to the Ct values of the control and are given as
log2
2DCt (DCt=Ct – Ct b2-microglobulin). Data are presented as means
6 S.E.M. of 3 independent experiments (3 NPC lines) each performed in
duplicate. A, The bar graph shows predominant expression of a2 and b
subunits in NPCs differentiated for 3 weeks that is significantly different
from all other glycine receptor subunits; significant differences between
log2
2DCt values are marked (***p,0.001, ANOVA and Newman-Keuls
post test). B, After 1 week of cell maturation the various glycine
receptor isoforms are not yet expressed to a significantly different
extent. The expression of a2, a4 and b subunits was markedly lower in
NPCs differentiated for 1 week than for 3 weeks.
doi:10.1371/journal.pone.0036946.g004
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neous process contrasting GABAA receptor expression in these
cells [24]. Previously, we could show that GABA induces [Ca
2+]i
increases in NPCs due to membrane depolarisation mediated by
GABAA receptors [24]. Activation of glycine receptors corre-
sponded with depolarising effects leading to a similar rise of
[Ca
2+]i in NPCs which could be completely inhibited by co-
application of strychnine. Calcium responses in NPCs revealed
only a weak sensitivity of excitatory glycine receptors to D-serine
that blocks glycine-evoked currents at NMDA receptors contain-
ing NR3 subunits [10]. Although human mesencephalic NPCs
express low amounts of NR3 [32], our calcium imaging data
suggest that glycine induces depolarisations by activation of
strychnine-sensitive glycine receptors.
Previous approaches to analyse human fetal neural progenitors
revealed intracellular Ca
2+ responses to glycine with a lower
magnitude and frequency (6%) after 2 to 4 weeks of differentiation
[43,44] suggesting an immature state of glycine receptor expres-
sion and function. Furthermore, a subpopulation of human
corneal stem cells responded to glycine in electrophysiological
experiments [45]. Strychnine-sensitive glycine receptors with a
depolarising function were detected indirectly by glycine-induced
suppression of inwardly-rectifying potassium channels in 80% of
neural stem-like cells derived from human umbilical cord blood
[46]. However, the functional relevance of glycine receptor-
mediated depolarisations for neurogenesis remains unclear. High
levels of glycinergic transmission may modulate neuronal excit-
ability causing membrane depolarisation and changes in intracel-
lular calcium that possibly regulate gene activity and affect neurite
outgrowth in immature mouse spinal neurons [20].
In differentiated human mesencephalic NPCs, the pro-
nounced expression of the importing Cl
2 co-transporter
NKCC1 contrasts KCC2 expression [24] which can result in
a high intracellular Cl
2 concentration and depolarising glycine-
effects. Neuronal maturation is associated with a downregulation
of NKCC1 and a stronger appearance of KCC2 [21–23] that
changes the direction of the ligand-gated Cl
2 current at
strychnine-sensitive glycine receptors from a depolarising to a
hyperpolarising one. We intended to test the role of glycine
receptors and NKCC1 for proliferation and differentiation of
NPCs in vitro by culturing the cells with the NKCC1-inhibitor
bumetanide (1 and 10 mM, [23]), the glycine-receptor antagonist
strychnine (1 and 10 mM), or additional glycine (1 and 10 mM)
while the media contained moderate glycine concentrations
(250–400 mM). However, such drug treatment of human
mesencephalic NPCs did not reveal significant changes com-
pared to untreated controls regarding markers for neurogenesis
and dopaminergic differentiation suggesting that glycine recep-
tors seem to have a limited functional impact on proliferation
and maturation of NPCs in vitro. The marked increase of
Figure 5. Immunocytochemistry of human mesencephalic NPCs after 3 weeks of standard differentiation in vitro. Photomicrographs
of NPCs immunoreactive for MAP2 (A) and glycine receptor subunits (B); nuclei were counter-stained with DAPI (C). Merged picture illustrates that
neuronal cells express glycine receptor subunits (D). Note, this glycine receptor antibody is specific for all subunits.
doi:10.1371/journal.pone.0036946.g005
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differentiation reflects neuronal maturation that is also apparent
in glycine receptor function (Fig. 1) and subunit expression
(Fig. 4) as well as in voltage-gated channel, GABAA- and
glutamate receptor function of NPCs [24].
Mature glycine receptors in the adult CNS display molecular
structures and physiological properties different from those in the
immature CNS. Immature glycine receptors are usually equipped
with a2o ra2b subunits while mature receptors are characterized
by their content of a1b and an increased sensitivity to several
modulators [7,20]. Most studies using recombinant glycine
receptors determined higher EC50 values for isoforms containing
b subunits than for the corresponding subtypes devoid of b
[41,47–49]. The glycine EC50 of receptors with a2o ra2b subunits
mainly ranged from 62 to 96 mM and from 66 mM to 157 mM,
respectively [41,49]. For the native glycine receptors in NPCs, we
calculated an EC50 of 99.2 mM. The glycine-induced currents
(EC70:300 mM) were all blocked by strychnine and showed a
rather low sensitivity to many modulators suggesting immature
receptor subtypes. In addition, the results of quantitative PCR
indicated a lack of a1 expression and a2 and b as predominant
subunits leading to the assumption that NPCs express glycine
receptors with a2 and/or a2b subunits.
In pharmacological experiments we tried to distinguish these
subtypes, although there are few compounds with sufficient
discriminatory capacity to identify the presence of either
homomeric a2 or heteromeric a2b glycine receptors [7]. While
the glycine responses of recombinant a2 receptors are inhibited by
the 5-HT3-antagonist tropisetron [41,47], the responses of a2b
subtypes can be potentiated by low tropisetron concentrations
[41]. In human mesencephalic NPCs, co-application of tropisetron
(1 mM) enhanced glycine-induced currents indicating the presence
of b subunits which are likely to contribute to this modulatory
glycine receptor site. A differential sensitivity to Zn
2+ that can
potentiate glycine-evoked currents at lower micromolar concen-
trations and inhibit recombinant heteromeric and neuronal
glycine receptors at higher concentrations [42,50] could also be
demonstrated for the receptor isoforms of NPCs suggesting a2b
subunit expression. Picrotoxin and the neurosteroid pregnenolone
sulphate are more potent inhibitors at homomeric than at
heteromeric glycine receptors [48,51–53]. Similar to recombinant
a2b subtypes [41,48], 10 mM picrotoxin and pregnenolone
sulphate caused only a moderate reduction of glycine-evoked
currents at native NPC receptors. Corresponding to the quanti-
tative PCR data for human mesencephalic NPCs, the elucidated
pharmacological profile indicates the expression of strychnine-
sensitive glycine receptors with a2b subunits.
In conclusion, the analyses of NPCs derived from human fetal
midbrain tissue demonstrate the expression of strychnine-sensitive
glycine receptors with an excitatory function following differenti-
ation but not during proliferation. Molecular and pharmacological
evidence suggest a predominant role for heteromeric a2b subtypes
which may indicate that cells are not fully maturated. This study
suggests that human mesencephalic NPCs acquire essential glycine
receptor properties during neuronal differentiation in vitro.
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